Pfizer, Inc. announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the 100 mg and 200 mg doses of abrocitinib, an oral, once-daily, Janus kinase 1 inhibitor, for marketing authorization to treat moderate to severe atopic dermatitis in adults who are candidates for systemic therapy.
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
The authors determined whether Lycopus lucidus Turcz (LLT) could improve 2,4‑dinitrochlorobenzene‑induced dermatitis and to verify the inhibitory effect of LLT on the expression of chemokines and pro‑inflammatory cytokines in the HaCaT immortalized keratinocyte cell line.
[Molecular Medicine Reports]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Scientists showed that in atopic dermatitis, IL-4 and IL-13 stimulated the expression of 3β-hydroxysteroid dehydrogenase 1, a key rate-limiting enzyme in sex steroid hormone synthesis, predominantly expressed by sebaceous glands in human skin.
[Proceedings of the National Academy of Sciences of the United States of America]
[zotpress userid=” items=’RE7NS7BX’ style=’apa’ cite=’yes’]
Researchers investigated whether coadministration with pimecrolimus, one of the topical calcineurin inhibitors, could influence the therapeutic potential of human umbilical cord blood MSCs in atopic dermatitis.
[Stem Cell Research & Therapy]
[zotpress userid=’6445218′ items=’ZUXENLPX’ style=’apa’ cite=’yes’]
Eli Lilly and Company and Incyte announced that the US FDA will not meet the Prescription Drug User Fee Act action date for the supplemental new drug application for baricitinib for the treatment of adults with moderate to severe atopic dermatitis (AD).
[Eli Lilly and Company, Inc.]
[zotpress userid=” items=’nan’ style=’apa’ cite=’yes’]
Researchers review the composition, structure and function of the ECM in cutaneous homeostasis, inflammatory skin diseases such as psoriasis and atopic dermatitis as well as infections as a paradigm for understanding its wider role in human health.
[Frontiers in Cell and Developmental Biology]
[zotpress userid=” items=’7FMJRX9G’ style=’apa’ cite=’yes’]
Researchers performed a phenome-wide association study and reported that the T allele of GPR65-intronic single-nucleotide polymorphism rs8005161, which reduced GPR65 signaling, showed a significant association with atopic dermatitis, in addition to inflammatory bowel diseases and asthma, as previously reported.
[Journal of Immunology]
[zotpress userid=” items=’3N7QZU8L’ style=’apa’ cite=’yes’]
The authors summarize the ongoing clinical studies that are targeting the microbiome in patients with skin disorders.
[Genes & Immunity]
[zotpress userid=’7753456′ items=’FJ2WVDPJ’ style=’apa’ cite=’yes’]
The authors summarized the mechanisms of several common neuropeptides in atopic dermatitis (AD) and hypothesized that neuropeptides may be the novel potential targets in AD treatment.
[zotpress userid=’7753456′ items=’MMZET6FR’ style=’apa’ cite=’yes’]
Scientists found that Tmem79−/− mice spontaneously develop interleukin-17-producing T-cell-driven skin inflammation. Comparative skin microbiome analysis revealed that the disease activity index is negatively associated with S. cohnii.
[zotpress userid=’7753456′ items=’PCA6AIJS’ style=’apa’ cite=’yes’]
The authors evaluate the development of (autoreactive) T cells and their response to (auto)antigens, as well as the role of the peripheral tolerance in autoimmunity in the pathophysiology of atopic dermatitis (AD), including the unmet needs and gaps.
[Journal of Autoimmunity]
[zotpress userid=’7753456′ items=’ITWJM7ZR’ style=’apa’ cite=’yes’]